Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 8/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7669043 | 0.87 | PTPN1 (0.41) | MLYCDRXRANR1H2NR1H3TSHR | |
| SCHEMBL4623433 | 0.83 | F2 (0.41) | — | |
| SCHEMBL3425497 | 0.82 | SERPINE1 (0.45) | — | |
| SCHEMBL7667615 | 0.80 | LMNA (0.49) | MLYCDRXRANR1H2NR1H3TSHR | |
| SCHEMBL272401 | 0.78 | KIF11 (0.40) | RXRANR1H2NR1H3HTTAPP | |
| SCHEMBL12252112 | 0.78 | PDK2 (0.41) | MLYCD | |
| SCHEMBL4044376 | 0.77 | CES2 (0.44) | MLYCDCES2CES1 | |
| SCHEMBL5339338 | 0.76 | ATM (0.44) | TSHRMAPTLMNA | |
| SCHEMBL5563726 | 0.75 | TSHR (0.54) | MLYCDNR1H2NR1H3TSHRHTT | |
| SCHEMBL2749395 | 0.74 | CACNA1G (0.39) | MLYCDRXRANR1H2NR1H3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694658-B1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA SA (FR) | 2009-02-25 | — | — | EP | claimed |
| US-20050165002-A1 | Process for the manufacture of a product of the thiazolo [3,4,5-de] [4,1]benzothiazepine type | AVENTIS PHARMA S.A. (FR) | 2005-07-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165002-A1 | Process for the manufacture of a product of the thiazolo [3,4,5-de] [4,1]benzothiazepine type | CYP2S1, CYP3A4, CYP2D6 | MLYCD 571/4885RXRA 2744/4885NR1H2 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.